KR101808903B1 - Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 - Google Patents

Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 Download PDF

Info

Publication number
KR101808903B1
KR101808903B1 KR1020147030871A KR20147030871A KR101808903B1 KR 101808903 B1 KR101808903 B1 KR 101808903B1 KR 1020147030871 A KR1020147030871 A KR 1020147030871A KR 20147030871 A KR20147030871 A KR 20147030871A KR 101808903 B1 KR101808903 B1 KR 101808903B1
Authority
KR
South Korea
Prior art keywords
mycoplasma
antigen
pcv2
lys
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147030871A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002748A (ko
Inventor
그레고리 피 니첼
제프리 이 갈빈
존 케이트 가렛
제임스 알 세컨드 쿨라윅
트레이시 엘 릭커
메간 마리 스무처
Original Assignee
조에티스 서비시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48140160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101808903(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 조에티스 서비시즈 엘엘씨 filed Critical 조에티스 서비시즈 엘엘씨
Publication of KR20150002748A publication Critical patent/KR20150002748A/ko
Application granted granted Critical
Publication of KR101808903B1 publication Critical patent/KR101808903B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020147030871A 2012-04-04 2013-04-03 Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신 Active KR101808903B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620189P 2012-04-04 2012-04-04
US61/620,189 2012-04-04
PCT/US2013/035091 WO2013152086A1 (en) 2012-04-04 2013-04-03 Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Publications (2)

Publication Number Publication Date
KR20150002748A KR20150002748A (ko) 2015-01-07
KR101808903B1 true KR101808903B1 (ko) 2017-12-13

Family

ID=48140160

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030871A Active KR101808903B1 (ko) 2012-04-04 2013-04-03 Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신

Country Status (32)

Country Link
US (2) US9125886B2 (cg-RX-API-DMAC10.html)
EP (2) EP2833909B1 (cg-RX-API-DMAC10.html)
JP (1) JP6271504B2 (cg-RX-API-DMAC10.html)
KR (1) KR101808903B1 (cg-RX-API-DMAC10.html)
AR (1) AR090614A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013243540C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014024775B1 (cg-RX-API-DMAC10.html)
CA (1) CA2869601C (cg-RX-API-DMAC10.html)
CL (1) CL2014002676A1 (cg-RX-API-DMAC10.html)
CO (1) CO7160027A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140438A (cg-RX-API-DMAC10.html)
CY (1) CY1121578T1 (cg-RX-API-DMAC10.html)
DK (1) DK2833909T3 (cg-RX-API-DMAC10.html)
ES (1) ES2719483T3 (cg-RX-API-DMAC10.html)
GT (1) GT201400212A (cg-RX-API-DMAC10.html)
HR (2) HRP20140956A2 (cg-RX-API-DMAC10.html)
HU (1) HUE042405T2 (cg-RX-API-DMAC10.html)
LT (1) LT2833909T (cg-RX-API-DMAC10.html)
MX (2) MX336502B (cg-RX-API-DMAC10.html)
MY (1) MY168549A (cg-RX-API-DMAC10.html)
NI (1) NI201400118A (cg-RX-API-DMAC10.html)
PH (1) PH12014502252A1 (cg-RX-API-DMAC10.html)
PL (1) PL2833909T3 (cg-RX-API-DMAC10.html)
PT (1) PT2833909T (cg-RX-API-DMAC10.html)
RS (1) RS58480B1 (cg-RX-API-DMAC10.html)
RU (1) RU2644256C2 (cg-RX-API-DMAC10.html)
SI (1) SI2833909T1 (cg-RX-API-DMAC10.html)
TR (1) TR201905176T4 (cg-RX-API-DMAC10.html)
TW (1) TWI504406B (cg-RX-API-DMAC10.html)
UA (1) UA114504C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013152086A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201407133B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515162A (ja) 2001-07-02 2005-05-26 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
AU2013370982C9 (en) 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
DK3072523T3 (en) * 2013-11-21 2019-04-08 Agricultural Tech Res Inst COMPOSITION FOR PREVENTION AND TREATMENT OF INFECTIONS WITH MYCOPLASMA
KR102360690B1 (ko) * 2013-12-03 2022-02-08 인터벳 인터내셔널 비.브이. Ｐｒｒｓ 및 로소니아 인트라셀룰라리스에 대한 돼지 백신
PL3076996T3 (pl) * 2013-12-03 2020-05-18 Intervet International B.V. Szczepionka przeciwko cirkowirusowi świń typu 2
CN104056265B (zh) * 2014-07-11 2016-04-27 江苏南农高科技股份有限公司 猪圆环病毒2型、猪繁殖与呼吸综合征二联疫苗及其制备方法
CN107073103A (zh) * 2014-09-12 2017-08-18 英特维特国际股份有限公司 用于保护猪免于猪流行性腹泻病毒的疫苗
CN107073102B (zh) * 2014-09-12 2021-06-25 英特维特国际股份有限公司 用于保护母猪的后代免于猪流行性腹泻病毒的疫苗
EP3229832A1 (en) * 2014-12-11 2017-10-18 Intervet International B.V. Process for ready-to-use pcv2/m.hyo combination vaccine
AU2016380864B2 (en) 2015-12-28 2019-10-31 Boehringer Ingelheim Animal Health USA Inc. M hyo multivalent vaccine and uses thereof
BR112018069100A2 (pt) * 2016-03-23 2019-01-29 Intervet International B.V. uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
BR112018069219A2 (pt) 2016-03-23 2019-01-22 Intervet Int Bv uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
CN109476711B (zh) * 2016-08-09 2023-08-08 财团法人农业科技研究院 防治猪鼻霉浆菌感染的组合物及生产该组合物的方法
UA124976C2 (uk) * 2016-12-14 2021-12-22 Зоетіс Сервісіз Ллс Вакцина для захисту тварини свині від зараження вірусом prrs
CA3045563C (en) * 2016-12-23 2022-05-03 Intervet International B.V. Combination vaccine for swine
CA3058281A1 (en) * 2017-04-13 2018-10-18 Intervet International B.V. Vaccines containing swine pathogens for associated non-mixed use
CN109280642B (zh) * 2017-07-21 2022-07-22 浙江海隆生物科技有限公司 CHO细胞株及其制备方法和使用该CHO细胞株制备猪圆环病毒2型Cap蛋白及其应用
JP7354106B2 (ja) 2017-12-04 2023-10-02 インターベット インターナショナル ベー． フェー． レプリコン粒子および油性アジュバントによるワクチン接種
CA3085535A1 (en) * 2017-12-22 2019-06-27 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
KR102769557B1 (ko) * 2021-11-19 2025-02-20 주식회사 이노백 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도
CN115851616A (zh) * 2022-09-23 2023-03-28 江西正邦科技股份有限公司 猪伪狂犬病毒毒株、猪圆环病毒2型毒株、四联灭活疫苗及其制备方法
CN119913202B (zh) * 2025-01-15 2025-09-19 北京华夏兴洋生物科技有限公司 用于制备猪三联疫苗的重组载体、重组病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
ES2097840T3 (es) 1987-11-03 1997-04-16 Syntex Inc Adyuvante de vacuna que comprende un tetrapoliol.
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
AU657907B2 (en) 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
DE69201441T3 (de) 1991-06-06 2008-12-04 Boehringer Ingelheim Vetmedica Gmbh Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
US5269315A (en) 1991-08-16 1993-12-14 The Regents Of The University Of California Determining the nature of brain lesions by electroencephalography
SG43852A1 (en) 1991-08-26 1997-11-14 Boehringer Animal Health Inc Sirs vaccine and diagnosis method
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
ES2194841T3 (es) 1991-11-15 2003-12-01 Pfizer Procedimiento de produccion de vacunas bacterianas gram negativas.
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP1820512B1 (en) 1994-05-10 2013-07-03 Boehringer Ingelheim Vetmedica, Inc. Improved modified live brsv vaccine
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
DE69740108D1 (de) 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
ID26951A (id) 1997-11-26 2001-02-22 Univ Iowa State Res Found Inc Vaksin mycoplasma hyopneumontae recombinan
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
NZ513289A (en) 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MXPA03011924A (es) * 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
JP2005515162A (ja) 2001-07-02 2005-05-26 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP1546357B1 (en) 2002-06-28 2013-08-07 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
CA2587321A1 (en) 2005-01-13 2006-07-20 Boehringer Ingelheim Vetmedica Gmbh Improved prrs vaccines
CN101277717A (zh) * 2005-09-09 2008-10-01 英特威国际有限公司 Pcv-2疫苗
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
DK2275132T3 (da) 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
RU2408386C2 (ru) * 2006-04-10 2011-01-10 Интервет Интернэшнл Б.В. Вакцина против микоплазмы и prrsv
KR101358517B1 (ko) 2006-04-10 2014-02-06 인터벳 인터내셔널 비.브이. 마이코플라즈마 ｐｒｒｓｖ에 대한 백신
US9056909B2 (en) 2007-11-06 2015-06-16 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
KR101320192B1 (ko) 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
ES2559445T3 (es) 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
EP2609428B1 (en) * 2010-08-27 2016-02-10 Intervet International B.V. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
MX362166B (es) 2012-03-07 2018-12-14 Ceva Sante Animale Nueva vacuna veterinaria.
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aust Vet J, Vol 75, Pages 504-511(1997)*

Also Published As

Publication number Publication date
CL2014002676A1 (es) 2014-12-12
BR112014024775B1 (pt) 2021-06-08
US20130266603A1 (en) 2013-10-10
TWI504406B (zh) 2015-10-21
KR20150002748A (ko) 2015-01-07
EP3508217A1 (en) 2019-07-10
CA2869601A1 (en) 2013-10-10
MX2014012016A (es) 2014-11-10
ZA201407133B (en) 2017-02-22
MX354773B (es) 2018-03-20
CY1121578T1 (el) 2020-05-29
RU2644256C2 (ru) 2018-02-08
CA2869601C (en) 2018-06-12
AU2013243540C1 (en) 2018-03-01
MY168549A (en) 2018-11-12
CR20140438A (es) 2014-11-12
JP2015512450A (ja) 2015-04-27
HK1207283A1 (en) 2016-01-29
EP2833909A1 (en) 2015-02-11
PT2833909T (pt) 2019-05-13
SI2833909T1 (sl) 2019-05-31
NI201400118A (es) 2015-03-05
UA114504C2 (uk) 2017-06-26
AU2013243540A1 (en) 2014-10-09
PH12014502252B1 (en) 2014-12-15
MX336502B (es) 2016-01-21
AR090614A1 (es) 2014-11-26
LT2833909T (lt) 2019-04-10
ES2719483T3 (es) 2019-07-10
RS58480B1 (sr) 2019-04-30
TW201345548A (zh) 2013-11-16
BR112014024775A2 (pt) 2017-07-11
GT201400212A (es) 2015-09-23
CO7160027A2 (es) 2015-01-15
HRP20140956A2 (hr) 2015-04-24
DK2833909T3 (en) 2019-04-01
US9650601B2 (en) 2017-05-16
EP2833909B1 (en) 2019-02-06
PH12014502252A1 (en) 2014-12-15
JP6271504B2 (ja) 2018-01-31
RU2014140108A (ru) 2016-06-10
HUE042405T2 (hu) 2019-06-28
US9125886B2 (en) 2015-09-08
HRP20190466T1 (hr) 2019-05-03
WO2013152086A1 (en) 2013-10-10
TR201905176T4 (tr) 2019-05-21
PL2833909T3 (pl) 2019-07-31
AU2013243540B2 (en) 2017-10-19
CN104271153A (zh) 2015-01-07
US20150284678A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
KR101747507B1 (ko) 마이코플라즈마 하이요뉴모니아 백신
KR102003620B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아 조합 백신
AU2013243540C1 (en) PCV/Mycoplasma hyopneumoniae/PRRS combination vaccine
CN104271153B (zh) Pcv/猪肺炎支原体/prrs组合疫苗
HK40072009A (en) Mycoplasma hyopneumoniae vaccine
HK40010886A (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
HK40010885A (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1206609B (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1207283B (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20141103

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160307

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160523

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170427

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20171121

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170627

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170328

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161227

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160725

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210929

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220921

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee